The successes and challenges of open-source biopharmaceutical innovation

Allarakhia, Minna

doi:10.1517/17460441.2014.905539

Cited by 7 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current business model of the pharmaceutical industry is unable to meet all medical needs, especially in the areas of neglected and rare diseases. In response, a variety of open source models have been implemented by a variety of organizations [56][57][58] (http://opensourcemalaria.org/; http:// www.osdd.net/) and there has been some recent discussion regarding the viability of such an open source business model expansion beyond the area of neglected diseases [59,60] (http:// www.opensourcepharma.net/). An interesting approach for drug development is the crowdsourcing of clinical trial design [61,62].…”

Section: Concluding Remarks and Discussionmentioning

confidence: 99%

Crowdsourcing in pharma: a strategic framework

Bentzien¹,

Bharadwaj²,

Thompson³

2015

Drug Discovery Today

View full text Add to dashboard Cite

Section: Concluding Remarks and Discussionmentioning

confidence: 99%

Crowdsourcing in pharma: a strategic framework

Bentzien¹,

Bharadwaj²,

Thompson³

2015

Drug Discovery Today

View full text Add to dashboard Cite

“…This is also linked to the discussion of open innovation in the biopharmaceutical industry [48]. In this industry, open innovation spans a wide range of activities from drug discovery through data sharing to product development and clinical test platforms [49]. Mazzola et al [50] empirically tested that open innovation is actually beneficial to firms' performance in biopharmaceutical industry.…”

Section: Business Models Of Biopharmaceutical Industrymentioning

confidence: 99%

Business Model Design for Latecomers in Biopharmaceutical Industry: The Case of Korean Firms

Song

Shin

2019

Sustainability

View full text Add to dashboard Cite

Given high business risks and interdependency with various organizations in biopharmaceutical industry, business model has become a key element for firms that aim to be more sustainable and profitable. Despite its growing importance, research on the business model design in biopharmaceutical industry is limited. In particular, there is a lack of research dealing with business models or strategies for latecomers. In the face of drastic changes such as market expansion and patent expiration, there has been growing interest in latecomer’s business model in the biopharmaceutical industry. This study identifies different types of business model designs using hierarchical clustering. Based on an empirical study of 313 biopharmaceutical firms in Korea, we find three types of business models: business diversified research firm, non-diversified research firm, and mature firm. We then compare the general characteristics and performances of each cluster. The findings indicate that business diversification of biopharmaceutical firms is beneficial in terms of profit. This implies that the biopharmaceutical firms in latecomer countries such as Korea are recommended to consider business diversification for sustainable management.

show abstract

“…During the past few years, there has been an important increase in open data initiatives to promote the availability of free research-based tools and information. 1 While there is still some resistance to open data in some chemistry and drug discovery elds, the availability of information has been a necessity for other research elds such as genomics, proteomics and bioinformatics. The Human Genome Project was paramount to the open-source movement in proteomics and genomics, demonstrating that a global community can be more successful and efficient in analyzing data than a single individual can.…”

Section: Introductionmentioning

confidence: 99%